Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer

<b>Background:</b> This phase II study evaluated the efficacy and safety of the histone deacetylase (HDAC) inhibitor, vorinostat, administered in combination with paclitaxel and carboplatin in patients with platinum sensitive recurrent ovarian cancer. <b>Methods:</b> Women wi...

Full description

Bibliographic Details
Main Authors: Hanieh Meteran, Anja Ør Knudsen, Trine Lembrecht Jørgensen, Dorte Nielsen, Jørn Herrstedt
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/13/3/897

Similar Items